GLP-1 Cost Surge Prompts US Health Plans and Employers to Roll Back Anti-Obesity Coverage

A sharp surge in spending on GLP-1 weight-loss medications is pushing state healthcare systems and private employers across the United States to slash drug coverage, exposing systemic financial pressure amidst an ongoing chronic illness crisis.

Healthcare spending on GLP-1 treatments skyrocketed by more than 500 percent between 2019 and 2024. Patient utilization is projected to expand significantly, rising from an estimated 10 million users in 2025 to 25 million by 2030. However, the rapidly growing price tag has led several major organizations and state entities to drastically scale back drug benefits.

This month, Massachusetts state Medicaid program, MassHealth, announced it will eliminate GLP-1 coverage for anti-obesity care. The decision directly impacts approximately 22,000 residents while saving the state an estimated $15 million annually. The decision follows similar moves in the private sector, where healthcare insurer Cigna recently removed GLP-1 weight-loss access for its corporate workforce. Industry research from the Business Group on Health reveals that 10 percent of employers currently offering weight-loss medication benefits intend to terminate them by 2027.

The pullbacks come at a time when population health needs remain acute. According to national health statistics, 76.4 percent of American adults live with at least one chronic health condition, and 51.4 percent manage two or more co-occurring illnesses. Obesity, which was officially designated as a disease by medical authorities just a decade ago, is linked to over 200 secondary medical conditions, including type 2 diabetes, chronic kidney disease, liver dysfunction, and cardiovascular and musculoskeletal disorders.

To mitigate the crisis among vulnerable populations, federal efforts led to the creation of the Bridge program, an 18-month initiative designed to grant GLP-1 access to eligible Medicare and Medicaid beneficiaries diagnosed with obesity and associated comorbidities. However, public health experts caution that the temporary program currently lacks a permanent follow-up framework to sustain long-term patient care.

Medical analysts emphasize that resolving the cost crisis requires moving away from binary decisions—choosing between unrestricted access or complete coverage bans—toward targeted, data-driven treatment strategies. Experts advocate for combining pharmaceutical interventions with multidisciplinary care models, including non-GLP medications, intensive behavioral therapy, nutritional guidance, physical activity, and bariatric surgery to achieve sustainable outcomes across the broader spectrum of chronic disease management.